The current valuation multiples are largely irrelevant in a traditional sense, as the absence of revenue renders P/E and EV/EBITDA metrics non-functional. Investors appear to be pricing the company as a binary option on regulatory approval, where the current P/B ratio indicates that the market assigns little value to the underlying assets beyond the potential for future clinical success.

While a current ratio of 1.90 might appear adequate in a stable industrial context, it is misleading for a clinical-stage biotech where the primary asset is a cash balance that is being consumed at a high rate. The lack of inventory or receivables means that liquidity is entirely dependent on the remaining cash, which warrants close monitoring for potential near-term financing requirements.

The presence of debt in a pre-revenue entity is inherently risky, as there is no operating cash flow to service interest or principal payments. This leverage, however small, may impose restrictive covenants or necessitate further dilution to ensure the company remains solvent while awaiting potential regulatory milestones.